Roche’s Kadcyla Fails To Better Herceptin In First-Line Breast Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sales estimates for Roche’s Kadcyla will be cut sharply after news the MARIANNE study didn’t show the antibody-drug conjugate performing better than Herceptin in treating first-line breast cancer. Firm’s early Alzheimer’s therapy gantenerumab also fails in Phase III.